Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England First patients implanted with Genio at UCLH, London Mont-Saint-Guibert, Belgium – December 13, 2024, 08:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alterna [ … ]

Nyxoah Reports Third Quarter Financial and Operating Results  FDA approval on track for first quarter 2025, U.S. commercial team build out in progress Company fully funded with cash until mid 2026 Mont-Saint-Guibert, Belgium – November 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a me [ … ]

Nyxoah Raises $27 Million through its At-the-Market Offering  Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus Mont-Saint-Guibert, Belgium – October 8, 2024 – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthroug [ … ]

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update Additional clinical data on patients suffering from Obstructive Sleep Apnea (OSA) demonstrate a clinically significant 71.0% median reduction in Apnea-Hypopnea index (AHI) while sleeping supine at 12 months compared with baseline. 82.0% of patie [ … ]

Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device FDA regulatory submission for the Company’s Genio® device is complete, U.S. approval on track for the end of 2024 U.S. commercial launch, expected at the beginning of 2025, fully funded with over €85 million in new capital raised Mont [ … ]

Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results FDA regulatory submission complete, U.S. approval on track for end of 2024 U.S. commercial launch fully funded with over €85 million in new capital raised Mont-Saint-Guibert, Belgium – August 6, 2024 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NY [ … ]

Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today  [ … ]

Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET / 6:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obst [ … ]